Serum level of soluble receptor for advanced glycation end products in asthmatic children and its correlation to severity and pulmonary functions.
Soluble receptor for advanced glycation end products (sRAGE) acts as a decoy receptor for RAGE which has several distinct pro-inflammatory ligands in the extracellular compartment, and is believed to afford protection against inflammation and cell injury. This study was conducted to measure serum sRAGE in asthmatic children and to assess its correlation with clinical and functional severity and to asthma phenotype according to sputum cytology. The study was conducted on 60 asthmatic children from the Pediatric Chest Clinic, Children's Hospital, Ain Shams University. The patients were divided according to asthma control and severity. sRAGE showed statistically significant lower levels in asthmatic patients (899.1 +/- 399.8 pg/mL) compared to the control group (1406.7 +/- 474.3 pg/mL, p = 0.000), with a cut off value of asthma diagnosis of 1080.4 pg/mL with a sensitivity and specificity of 77% and 75%, respectively. Uncontrolled and severe asthmatic subgroups showed lower levels of sRAGE, cut off value of sRAGE for the severity of asthma was 829 pg/mL with 89% sensitivity and 81% specificity. Asthmatic patients stratified according to sputum cytology revealed that those with > 2% eosinophils and > or = 40% neutrophils showed lower levels of sRAGE (710 +/- 258 pg/mL) compared to those with > 2% eosinophils and < 40% neutrophils (1064 +/- 431 pg/mL) (p = 0.000). There was a highly significant positive correlation between sRAGE levels and FEV 1% (r = 0.41, p < 0.01), a highly significant negative correlation with eosinophilic count and total IgE (r = -0.49 and -0.39, respectively, p < 0.01). Serum level of sRAGE may correlate with severity of bronchial asthma clinically and functionally. It may be a target of future therapeutic interventions.